Shares of Moderna (NASDAQ: MRNA) jumped 7.8% on Thursday after the drugmaker announced several notable advances during its annual research and development update.
Moderna is developing a single-dose vaccine, known as mRNA-1073, that includes boosters against both COVID-19 and seasonal flu. The biotech is also evaluating four development candidates against coronavirus variants, including Delta, with three already in clinical trials.
Moderna's stock price rose sharply following its R&D update on Thursday. Image source: Getty Images.
Source Fool.com